Tyr51

Site Information
sVtDPEkyPHMLSVK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3672595

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	liver cancer, surrounding tissue ( 2 )
Relevant cell line - cell type - tissue:	'liver, para-cholangiocellular carcinoma tissue' ( 1 ) , liver ( 2 )

References
1	Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640 21253578 Curated Info
2	Gu T (2009) CST Curation Set: 7529; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
3	Yu J (2006) CST Curation Set: 2143; Year: 2006; Biosample/Treatment: tissue, larynx/-; Disease: laryngeal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info